<rdf:RDF xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
   <ow:Publication rdf:about="oai:digibug.ugr.es:10481/96774">
      <dc:title>Nanoparticles Bounded to Interfering RNAs as a Therapy for Pancreatic Cancer: A Systematic Review</dc:title>
      <dc:creator>Lara, Patricia</dc:creator>
      <dc:creator>Quiñonero Muñoz, Francisco José</dc:creator>
      <dc:creator>Ortiz Quesada, Raúl</dc:creator>
      <dc:creator>Prados Salazar, José Carlos</dc:creator>
      <dc:creator>Melguizo Alonso, Consolación</dc:creator>
      <dc:subject>nanoparticles</dc:subject>
      <dc:subject>pancreatic cancer</dc:subject>
      <dc:subject>siRNA</dc:subject>
      <dc:description>This work was supported in part by Instituto de Salud Carlos III (PI19/01478-FEDER and PMPTA22/00136-FEDER). Funding for open access charge: Universidad de Granada/CBUA.</dc:description>
      <dc:description>Pancreatic cancer is one of the tumors with poor prognosis and low survival due to late diagnosis, high resistance, and very limited effective therapeutic options. Thus, new pharmacological treatments are necessary to improve the prognosis of patients. In this context, nanoparticles represent an efficient system for transporting and administering therapeutic molecules. Furthermore, siRNA can be used in cancer treatment to selectively inhibit the expression of any target gene. Therefore, nanoparticles associated with siRNA have been tested as a new therapeutic strategy to solve the pancreatic cancer treatment failure in the clinical setting. The current article presents a systematic revision of the literature of the last 10 years in which nanoparticles loading siRNA are used in pancreatic cancer. This research was carried out in three databases (PubMed, Scopus, and Web of Science) obtaining 164 articles from which 37 were selected. Our results show an overall view of the high effectiveness of this new therapy that combines nanoparticles with genetic therapy in pancreatic cancer suggesting that siRNA-based medicines will likely open up a new therapeutic era in the treatment of this type of tumors.</dc:description>
      <dc:date>2024-11-08T12:43:47Z</dc:date>
      <dc:date>2024-11-08T12:43:47Z</dc:date>
      <dc:date>2024-11-08</dc:date>
      <dc:type>journal article</dc:type>
      <dc:identifier>Lara, P., Quiñonero, F., Ortiz, R., Prados, J. and Melguizo, C. (2024), Nanoparticles Bounded to Interfering RNAs as a Therapy for Pancreatic Cancer: A Systematic Review. WIREs Nanomed Nanobiotechnol, 16: e2013. https://doi.org/10.1002/wnan.2013</dc:identifier>
      <dc:identifier>https://hdl.handle.net/10481/96774</dc:identifier>
      <dc:identifier>10.1002/wnan.2013</dc:identifier>
      <dc:language>eng</dc:language>
      <dc:rights>http://creativecommons.org/licenses/by-nc-sa/4.0/</dc:rights>
      <dc:rights>open access</dc:rights>
      <dc:rights>Atribución-NoComercial-CompartirIgual 4.0 Internacional</dc:rights>
      <dc:publisher>Wiley</dc:publisher>
   </ow:Publication>
</rdf:RDF>